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a b s t r a c t
Small-caliber cerebral vessels change their diameters in response to alterations of key
metabolite concentrations such as carbon dioxide or oxygen. This phenomenon, termed
the cerebral vasomotor reactivity (CVMR), is the basis for blood ﬂow regulation in the brain in
accordance with its metabolic status. Typically, CVMR is determined as the amount of
change in cerebral blood ﬂow in response to a vasodilating stimulus, which can be measured
by various neuroimaging methods or by transcranial Doppler. It has been shown that CVMR
is impaired in cerebrovascular diseases, but there is also evidence of a similar dysfunction in
neurodegenerative disorders. Here, we review studies that have investigated CVMR in the
common neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and
multiple sclerosis. Moreover, we discuss potential neurodegenerative mechanisms respon-
sible for the impairment of CVMR.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Cerebral blood ﬂow (CBF) is controlled by three principle
mechanisms – pressure regulation, neurogenic regulation, and
metabolic regulation [1]. Pressure regulation, also referred to
as the cerebral autoregulation, is a mechanism responsible for
maintaining a constant CBF within a certain range of arterial
blood pressure, whereas neurogenic regulation is the control
of the vascular tone by both peripheral nervous system as well
as central nervous system (CNS). Metabolic regulation is a
mechanism responsible for keeping balance between energy
supply and demand in the CNS. At the cellular level, these* Corresponding author at: Second Department of Neurology, Institut
Poland. Tel.: (+48 22) 45 82 537, 84 27 683; fax: (+48 22) 84 24 023.
E-mail address: czlonkow@ipin.edu.pl (A. Członkowska).
http://dx.doi.org/10.1016/j.pjnns.2016.07.011
0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Sthree mechanisms interact within a functional unit, termed
the neurovascular unit (NVU), consisting of vascular cells, glial
cells and perivascular nerves [2] (Fig. 1).
1.1. Metabolic regulation of CBF and cerebral vasomotor
reactivity
It has been shown that CBF rises in response to an increasing
arterial carbon dioxide concentration and decreasing arterial
pH, whereas oxygen has the opposite effect [3]. These effects
are mediated by changes in diameters of cerebral arterioles,
and therefore, this phenomenon is described as the cerebral
vasomotor reactivity (CVMR). It should be noted that CVMR ise of Psychiatry and Neurology, ul. Sobieskiego 9, 02-957 Warsaw,
p. z o.o. All rights reserved.
Fig. 1 – Control of cerebral blood flow and the neurovascular
unit. At the cellular level, CBF is controlled by the NVU – a
tripartite unit consisting of neurons (blue), vascular cells
(red), and glial cells (yellow). (1) Pressure regulation is
achieved by a reflex constriction of vascular cells in
response to increased flow velocity (shear stress) and
increased transmural pressure. (2) Neurogenic regulation is
the control of vascular tone by both autonomic neurons
(extrinsic innervation) and CNS neurons/interneurons
(intrinsic innervation), (3) Metabolic regulation is
responsible for maintaining appropriate levels of e.g.
oxygen, carbon dioxide. CBF–cerebral blood flow, CVMR,
cerebral vasomotor reactivity; NVU, neurovascular unit.
(For interpretation of the references to color in this
figure legend, the reader is referred to the web version of
this article.)
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al hyperemia), whereby changes in CBF occur in accordance,
temporally and spatially, with local brain activity.
1.2. Measurement of CVMR
In principle, CVMR is determined by measuring CBF changes
following a vasoactive challenge. CBF can be determined
directly by neuroimaging methods (e.g. single photon emis-
sion computed tomography – SPECT, positron emission
tomography – PET, functional magnetic resonance imaging –
fMRI) or indirectly through the measurement of blood ﬂow
velocity (FV) in major cerebral arteries by transcranial Doppler
(TCD). This latter approach is based on the assumption that
vasoactive substances exert their effects by acting on small
cerebral arterioles, whereas the effect on the major cerebral
arteries, in which measurements are made, is negligible [4].
Among all the stimuli used for the assessment of CVMR, CO2 is
regarded as the most reliable [5]. However, other vasodilating
stimuli such as intravenous acetazolamide and breath-
holding are also commonly used. Lastly, several CVMR indexes
have been used so far. Earlier studies used a qualitative
approach and classiﬁed CVMR in individuals as either present
(observable increase in CBF after vasoactive challenge) or
absent (no observable change in CBF). More recent studies
have used quantitative indexes such as a relative increase inCBF or FV following a vasoactive challenge, which is
sometimes additionally normalized per each mm Hg of the
increase in end-tidal partial pressure of CO2 (ETpCO2) that
approximates arterial pCO2. Finally, in the breath-holding test,
CVMR is expressed as the breath-hold index (BHI), which is a
relative change in FV upon apena divided by the time of breath
holding in seconds (usually 30 s).
2. CVMR in neurodegenerative diseases
Below, we review studies that have assessed CVMR in the
common neurodegenerative diseases – Alzheimer's disease
(AD), Parkinson's disease (PD), and multiple sclerosis (MS).
2.1. Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease that
accounts for approximately 70% of dementia cases [6].
Although amyloid beta deposition in the CNS is considered
as the central pathological feature of AD, the importance of
vascular mechanisms has also been underscored [7]. There
have been numerous studies investigating CVMR in AD, and
they have been reviewed elsewhere [8,9]. Therefore, they are
not described here in detail but are presented in Table 1. In
summary, the evidence, especially that coming from more
recent studies with appropriate control groups, indicates an
impaired CVMR in AD. The clinical signiﬁcance of CVMR is
reﬂected by the fact that its impairment is associated with an
increased risk of both conversion from mild cognitive
impairment to AD [10,11] and cognitive decline in AD [12].
However, it remains less clear whether CVMR is affected
differentially in AD and vascular dementia (VD).
2.2. Parkinson's disease
Parkinson's disease (PD) is a common neurodegenerative
disease resulting primarily from the degeneration of dopami-
nergic neurons of the substatia nigra, which leads to the
development of motor symptoms such as tremor, rigidity, and
bradykinesia. Moreover, non-motor symptoms such neuro-
psychiatric symptoms (e.g. depression, dementia, psychotic
disturbances) and autonomic symptoms can be present as well
[34]. Autonomic dysfunction in PD manifests for instance as
orthostatic hypotension [35] and can affect CBF and CVMR as
well (see Table 2) [36,37].
Two out of three studies using TCD and breath-hold as a
vasoactive stimulus reported signiﬁcantly impaired BHI in PD
patients in comparison to healthy controls [38–40]. In
contrast, studies using fMRI for the assessment of CVMR
did not show signiﬁcant differences between PD patients and
controls [41,42]. Similarly, the change in FV induced by
hyperventilation was normal in PD patients [43]. Moreover,
studies without control groups also indicated that CVMR in PD
patients might be normal [44,45]. Because of the inconsisten-
cy of results between studies and a low number of studies that
typically enrolled small samples, no deﬁnite conclusion as to
a possible CVMR impairment in PD can be made. However, it
seems that CVMR is not affected by dopaminergic treatment
[38,39,41,45].
Table 1 – Studies on cerebral vasomotor reactivity in Alzheimer's disease patients.
Ref. CBF measurement Vasoactive
stimulus
Number of
patients
Control group Conclusions
[13] TCD Rebreathing 17 AD Yes, n = 17 CVMR decreased in AD (40%
increase in FV vs. 60% in controls)
[14] TCD Breath-hold 40 AD Yes, n = 40 BHI lower in AD
[15] SPECT Acetazolamide 12 AD Yes, n = 9 CVMR signiﬁcantly decreased in AD.
[16] TCD 6% CO2 inhalation,
hyperventilation
60 AD; 58 VD Yes, n = 62 CVMR equally decreased in AD and
VD (60% increase in FV vs. 80% in
controls)
[17] SPECT 5% CO2 inhalation 5 AD Yes, n = 21 CVMR in gray matter preserved in AD
[18] BOLD-fMRI 5% CO2 inhalation 17 AD Yes, n = 17 CVMR impaired in the prefrontal,
anterior cingulate, insular areas.
[19] TCD Acetazolamide 9 AD; 9 VD No No signiﬁcant differences between
AD and VD
[20] SPECT Acetazolamide 35 AD; 16 stroke No CVMR in AD preserved in contrast to
stroke.
[21] BOLD-MRI 7% CO2 inhalation 9 AD; 7 MCI Yes, n = 11 CVMR impaired in AD and MCI, most
pronounced in the occipital and
parietal lobes
[22] TCD 7% CO2 inhalation,
hyperventialtion
12 AD patients Yes, n = 24 CVMR decreased in AD (40%
increase in FV vs. 80% in controls).
No differences to hyperventilation.
[23] SPECT Acetazolamide 12 AD; 11 MCI No CVMR in AD and MCI preserved
[24] TCD and ASL-MRI 5% CO2 inhalation 26 AD; 23 VD No No differences between AD and VD
in TCD. CVMR lower in AD in both
frontal lobes
[25] SPECT Hyperventilation 8 AD; 9 MID No CVMR in AD and MID preserved;
however, in AD regional CVMR
decreased in temporal lobes
[26] PET 8% CO2 inhalation 5 AD Yes, n = 16 CVMR in AD preserved
[27] PET 5% CO2 inhalation 5 AD; 5 VD Yes, n = 5 CVMR normal AD in contrast to VD
patients
[28] TCD Breath-hold 10 AD; 10 MID Yes, n = 20 CVMR to hypercapnia decreased in
MID but not in AD.
[29] TCD Breath-hold 23 AD; 16 AH Yes, n = 25 BHI lower in AD and AH than in
controls
[30] CT Acetazolamide 10 AD Yes, n = 10 CVMR impaired in AD, in the frontal,
parietal, and temporal cortices.
[31] SPECT Acetazolamide 33 AD; 18 VD No CVMR response seen in 76% of AD
patients and 18% of VD patients
[32] TCD Hyperventilation,
breath-hold,
rebreathing
20 AD; 20 MID Yes, n = 25 CVMR to hypercapnia decreased in
MID but not in AD. CVMR to
hypocapnia equally impaired in AD
and MID.
[33] BOLD-fMRI 7% CO2 inhalation 20 AD; 15 MCI Yes, n = 28 CVMR impaired in AD in all brain
regions except for the insula and
subcortical nuclei.
AD, Alzheimer's disease; AH, amyloid hemorrhage; ASL-MRI, arterial spin labeled magnetic resonance imaging; BHI, breath-hold index; BOLD-
fMRI, blood-oxygen-level-dependent functional magnetic resonance imaging; CBF, cerebral blood ﬂow; CT, computed tomography; CVMR,
cerebral vasomotor reactivity; FV, ﬂow velocity; MCI, mild cognitive impairment; MID, multi-infarct dementia; PET, positron emission
tomography; SPECT, single-photon emission tomography; TCD, transcranial Doppler; VD, vascular dementia.
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MS is an inﬂammatory, demyelinating disease of the CNS. The
role of inﬂammation in MS is undisputed – it is present at all
stages of the disease and has been the primary target for drug
development [46]. However, the contribution of neurodegen-
erative processes in the disease pathogenesis has been
increasingly recognized, especially with respect to possible
mechanisms of progression. These may include axonal
degeneration, mitochondrial injury, energy failure, hypoxia,
oxidative damage, iron accumulation or global cerebralhypoperfusion [47,48]. Interestingly, CVMR in MS may be
impaired as well. Uzuner et al. studied 12 relapsing-remitting
MS patients and 11 healthy controls [49]. A breath-hold of 15-s
was used as a vasoactive stimulus, and CVMR was expressed
as a percentage ratio between the maximal and minimal ﬂow
velocity recorded during the period of breath-holding, as
measured by TCD in the MCA. In MS patients, measurements
were made on three time points – before the ﬁrst and after the
last methylprednisolone infusion as well as one month after
discharge. Although MS patients had lower CVMR values
(46.5% prior to treatment, 48.3% after treatment, and 50.9% in
Table 2 – Studies on cerebral vasomotor reactivity in Parkinson's disease patients.
Ref. CBF measurement Vasoactive
stimulus
Number of
patients
Control group Conclusions
[38] TCD Breath-hold 12 PD Yes, n = 12 No differences in BHI between PD patients
and age-matched controls
[39] TCD Breath-hold 15 PD Yes, n = 15 BHI signiﬁcantly lower in PD patients than in
controls
[40] TCD Breath-hold 11 PD Yes, n = 11 BHI signiﬁcantly lower in PD patients than in
controls
[41] BOLD-fMRI 7% CO2 inhalation 10 PD Yes, n = 8 Whole-brain and regional CBF increased
similarly in PD patients (1.62%) and controls
(1.48%).
[42] ASL-fMRI Close-circuit
rebreathing
14 PD Yes, n = 14 Difference in whole-brain CBF not signiﬁcant
between PD patients and age-matched
controls. Large variability of CVMR values.
[43] TCD Hyperventilation 13 PD Yes, n = 22 No signiﬁcant difference in FV between PD
patients (20–30%) and healthy controls
(40%)
[44] TCD Acetazolamide
injection
9 PD
10 MSA
5 PAF
No No differences between patient groups in
percentage increase in FV in MCA and VA that
were within the normal range of the
laboratory.
[45] TCD 8% CO2 inhalation 44 PD No Percentage increase in FV in MCA normalized
by increase in EtC02 in mm Hg less than 5%
(arbitrary lower limit value) observed in 34.1%
of PD patients. Mean value of 8.4% in PD
patients greater than the mean value in
healthy subjects from an earlier study
ASL-MRI, arterial spin labeled magnetic resonance imaging; BHI, breath-hold index; BOLD-fMRI, blood-oxygen-level-dependent functional
magnetic resonance imaging; CBF, cerebral blood ﬂow; MCA, middle cerebral artery; MSA, multiple system atrophy; PAF, pure autonomic
failure; PD, Parkinson's disease; CVMR, cerebral vasomotor reactivity; FV, ﬂow velocity; TCD, transcranial Doppler; VA, vertebral artery.
Fig. 2 – Blood–brain barrier disruption and other possible
factors causing impairment of cerebral vasomotor
reactivity – description in text (Sections 3 and 4).
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statistically signiﬁcant. In another study, Marshall et al. [50]
assessed CVMR in 19 MS patients and an equal number of
controls. They measured CBF by fMRI in a baseline condition
and following 5% CO2 inhalation. CVMR was expressed in
percentage terms as a ratio between the relative increase in
CBF per each mm Hg of end-tidal CO2 change. MS patients had
a signiﬁcantly lower CVMR (3.56%) than healthy controls
(5.08%) in the gray as well as in the white matter (6.1% vs. 4.0%,
respectively). Moreover, gray matter CVMR was impaired
particularly in the temporal, parietal, sublobar, and limbic
regions, and correlated negatively with lesion volume and
positively with gray matter volume normalized for total
intracranial volume.
3. Mechanisms of CVMR impairment in
neurodegenerative diseases
Although the cause of CVMR impairment in neurodegenera-
tive disease is not clear, several potential factors might
contribute to this phenomenon. For the purpose of clarity,
we divide them into (1) vascular factors, (2) glial factors, and (3)
neuronal factors – according to the three cell types comprising
the NVU (Fig. 2).
3.1. Vascular factors
Vascular risk factors such as hypertension, hypercholesterol-
emia, smoking or obesity frequently coexist with AD, PD andMS [51–53]. Consequently, they may contribute to cerebral
vessel disease, and thus, to the impairment of CVMR.
Moreover, it is postulated that vascular factors might
additionally aggravate the course of neurodegenerative dis-
eases, and in clinical practice it is often difﬁcult to distinguish
whether the disease process is driven by a neurodegenerative
or vascular pathology.
Amyloid beta is considered to play a key role in the
pathogenesis of AD – its deposits are seen in the nervous tissue
but also in the walls of cerebral vessels. Soluble amyloid beta
may directly constrict cerebral arterioles [54,55], and once
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of cerebral amyloid angiopathy [56] as well as in amyloid
hemorrhage (AH) and AD patients [29,57]. Amyloid beta
compromises the ability of cerebral endothelial cells to
produce vasodilators and thus can impair not only CVMR
but also other mechanisms regulating CBF such as auto-
regulation (inadequate blood supply during hypotension) and
neurovascular coupling (inadequate blood supply during
increased brain activity) [58]. In contrast, the tau protein,
which has also been implicated in the pathology of AD and PD,
has been recently shown to increase CVMR in transgenic mice
expressing this molecule [59].
Blood–brain barrier (BBB) disruption might be another
factor contributing to CVMR impairment in neurodegenerative
disorders [60–62]. The hemodynamic consequences of BBB
breakdown may include albumin extravasation leading to
perivascular edema and subsequent cerebral hypoperfusion
[2], which is a well-established feature of AD, PD and MS
[48,63,64]. It has been reported that peritumoral gray-matter
edema reduces both local CBF and CVMR, with improvement
upon tumor resection [65]. This ﬁnding might explain how
perivascular edema caused by BBB breakdown can lead to both
cerebral hypoperfusion and impaired CVMR in neurodegener-
ative diseases. In the case of MS, one would also expect
glucocorticoid treatment to improve CVMR as it might reduce
perivascular edema by restoring BBB [49].
CVMR impairment could also be caused by an increase in
the concentration of vasoconstrictive agents. For instance,
endothelin-1 (ET-1) – a potent vasoconstrictor, is overex-
pressed in the cerebral vessels of AD and MS patients [66,67]. In
MS, there is also evidence that ET-1 is elevated in both serum
and cerebrospinal ﬂuid [68–71]. In AD, a pro-contractile state of
the cortical arterioles can also be reﬂected by an increased
expression of the serum response factor and myocardin –
nuclear transcription factors that orchestrate smooth muscle
contraction [72] as well as an increased expression of thrombin
in endothelial cells [73]. In MS, inﬂammatory mediators, such
as tumor necrosis factor alpha, might also contribute to
vasoconstriction [74].
3.2. Glial factors
Glial cells, and especially astrocytes that directly abut vascular
cells, may inﬂuence the contractility of cerebral arterioles.
Moreover, glial cells play an important role in the neurode-
generative and/or neuroinﬂammatory processes.
Reactive astrocytes, i.e. hypertrophied astrocytes that
overexpress GFAP (glial ﬁbrillary acidic protein) have been
described in virtually all CNS disorders including AD, PD, and
MS [75]. Although reactive astrocytes may exert some
beneﬁcial effects, they could also contribute to CVMR
impairment through the production of ET-1 and possibly
other vasoconstrictors. ET-1-expressing astrocytes have been
described in AD and MS patients [71,76,77]. Interestingly,
reactive astrocytes might lead to a decreased CVMR in a mouse
model of Huntington's disease by promoting dysfunctional
angiogenesis and reducing the number of pericytes [78].
Another way in which glial cells could contribute to the
impairment of CVMR might be associated with their involve-
ment in oxidative stress pathways [79,80]. The research ofZhang et al. [81,82] shows how oxidative stress may lead to
impaired CVMR. In the tail-suspended hindlimb unweighting
rat (a model of microgravity), the authors showed that
acetylcholine-induced vasodilation in the basilar and common
carotid arteries was reduced, which was associated with a
seemingly paradoxical increase in NO arterial concentration,
and a parallel increase in the superoxide radical (O2
) content
in the arterial wall. Subsequently, the authors demonstrated
that a pharmacological inhibition of the NADPH-oxidase, a
major source of the superoxide radical, signiﬁcantly improved
the dilation of cerebral arteries and restored NO concentration
to near-normal values. This shows that the vasodilating effect
of NO may be inactivated in an oxidative milieu. Notably,
increased levels of nitric oxide in various bodily ﬂuids have
been reported in patients with AD, PD and MS [83–86] and in AD
NO levels correlated with the concentration of oxidized low-
density lipoproteins, a marker of oxidative stress [84]. These
ﬁndings might be explained by the fact that under pathological
conditions associated with oxidative stress, NO is generated
abundantly by glial cells through the inducible NO synthase
(iNOS), but instead of contributing to vasodilation, NO is
transformed into toxic reactive nitrogen species (RNS) [87].
Glial pathology may also cause BBB dysfunction [62],
leading for instance to cerebral hypoperfusion, but also to
the perivascular leakage of hemoglobin-containing red-blood
cells, which might result in iron-induced ROS formation [2].
3.3. Neuronal factors
It has been shown that cholinergic projections originating
from the nucleus basalis induce cerebral vasodilation directly
through the release of acetylcholine and indirectly through the
stimulation of NO-releasing interneurons [1]. Thus, choliner-
gic dysfunction could lead to a less efﬁcient cerebral
vasodilation, and consequently to an impaired CVMR. Impor-
tantly, the cholinergic system is almost invariably impaired in
AD [88], and there is evidence of a cholinergic deﬁcit in PD and
MS [89,90]. Moreover, it has been shown that CVMR improves
in AD and VD patients following the administration of
galantamine – a cholinesterase inhibitor [91].
Finally, cerebral hypoperfusion observed in neurodegener-
ative diseases may lead to a state of hypoxia resulting in ROS
production by neuronal mitochondria [92–95].
4. Conclusions
There is evidence suggesting that CVMR might be impaired in
neurodegenerative diseases. In AD, most studies with age-
matched control groups reported a signiﬁcant impairment of
CVMR, and studies reporting normal CMVR in AD often did not
make direct comparisons with age-matched control groups
and/or were underpowered. Due to a low number of studies in
PD and MS, it is less clear whether CVMR in these diseases is
signiﬁcantly impaired as well. In MS, only two studies have
been performed so far, but both reported a decrease in CVMR in
MS patients. There is less certainty regarding CVMR in PD as
the studies are largely inconsistent.
The reasons for CVMR impairment in neurodegenerative
diseases are not clearly established, and it is likely that the
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 4 5 5 – 4 6 2460etiology is multifactorial and multidirectional. Conceptually,
the disruption of BBB could be thought of as a starting point in
a cascade of processes leading to the impairment of CVMR,
although it would be difﬁcult to prove that this event is
primary in the temporal sense (Fig. 2). By causing perivascular
edema and thus a mass effect, BBB breakdown could diminish
both CBF and CVMR. In turn, this could lead to hypoxia and/or
energy failure with resultant ROS generation by dysfunctional
neuronal mitochondria and degeneration of neurons produc-
ing vasodilating neurotransmitters (acetylcholine, NO). More-
over, BBB disruption could provoke a hypercontractile state of
the cerebral endothelium and the activation of glial cells
expressing vasoconstrictors, such as ET-1, and generating
ROS/RNS.
Although the contribution of CVMR impairment to the
pathogenesis of neurodegenerative diseases is not certain, it
might be suspected that a reduced cerebrovascular reserve is
an additional deteriorating factor in disease progression.
Therefore, it would be worthwhile to include CVMR measures
in studies assessing prognostic factors and/or treatment
interventions.
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